SmartPeptide
CognitiveLimited human evidence

Semax

Heptapeptide analog of ACTH(4-10) studied in Russia for cognitive and neuroprotective effects after stroke.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Russian post-stroke and cognitive-performance studies; some BDNF/neurotrophic mechanism work.

What's still experimental

Limited western replication. Cognitive-enhancement claims in healthy adults need larger trials.

Anecdotal / community reports

Focus and clarity reports are common; outcomes depend on dose, formulation, and individual factors.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

Live research

Updated hourly · sourced from PubMed + ClinicalTrials.gov
PubMed papers
228
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
0 total registered

Known risks

Mostly Russian-source data; not approved by FDA.

Reported side effects

Limited safety data in Western populations.

What requires medical supervision

Not FDA-approved. Limited western safety data.

Questions for your clinician

  • Is there independent (non-Russian) replication?
  • What baseline cognitive testing would we do to track effect?

Editorially curated references

Discussions about Semax

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all Semax discussions Native, moderated, no buying or selling